Saturday 17 October 2026
Export SXTP’s income statement to Excel — free account
60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS grew 82.0% and free cash flow fell 54.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.04
−4.44%
Follow SXTP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 122.64 | 14.04 | 1.80 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 2,076.00 | 271.20 | 32.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 2 | 3 | 3 | 3 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.26 | 0.08 | 0.23 | 0.47 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 3 | 6 | 1 | 0 | 1 | 1 | ||||
| Gross margin, % | — | — | — | — | 72.43 | 86.61 | 15.41 | (87.15) | 43.53 | 44.52 | |||||
| EBT | — | — | — | — | (3) | (4) | (6) | (4) | (8) | (7) | |||||
| EBT margin, % | — | — | — | — | (119.53) | (67.04) | (1,208.39) | (1,503.79) | (1,167.72) | (522.91) | |||||
| Net income | — | — | — | — | (3) | (4) | (6) | (4) | (8) | (7) | |||||
| Depreciation | — | — | — | — | 0 | 1 | 1 | 2 | 4 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.44 | 1.10 | 51.64 | 15.37 | 5.98 | 2.10 | ||||
| Earnings | — | — | — | — | (0.52) | (0.74) | (626.38) | (237.69) | (74.20) | (11.73) | |||||
| Cash flow | — | — | — | — | (0.03) | (0.11) | (102.02) | (275.33) | (49.54) | (10.22) | |||||
| Capex | — | — | — | — | 0.00 | (0.01) | (6.08) | (7.02) | (1.59) | (0.33) | |||||
| Free cash flow | — | — | — | — | (0.03) | (0.12) | (108.10) | (282.35) | (51.13) | (10.55) | |||||
| Book value | — | — | — | — | (3.03) | (3.14) | (2,439.30) | 290.79 | 34.69 | 5.04 | |||||
| Shares, m | — | — | — | — | 6 | 6 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 25.28 | 25.28 | 25.28 | 16.08 | 4.32 | 0.97 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | 28.01 | 28.01 | 28.01 | 12.45 | 1.14 | (0.12) | |||||
| EV/FCF | — | — | — | — | (10.76) | (10.76) | (10.76) | (0.68) | (0.13) | 0.02 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (1) | (5) | (6) | (7) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | 0 | (1) | (1) | (5) | (6) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | 1 | (23) | 4 | 4 | 3 | ||||
| Total debt | — | — | — | — | 19 | 19 | 5 | — | — | — | |||||
| Net debt | — | — | — | — | 19 | 19 | 5 | (2) | (3) | (3) | |||||
| Shareholders’ equity | — | — | — | — | (18) | (18) | (24) | 5 | 4 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (212.61) | (459.49) | (82.94) | (117.36) | (132.40) | ||||
| ROIC | — | — | — | — | 0.00 | (171.52) | 0.00 | (121.31) | (1,070.52) | (771.42) | |||||
| ROE | — | — | — | — | 0.00 | 23.85 | 29.23 | 25.78 | 148.93 | 124.83 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
60 Degrees Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.3M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.2M | — (loss-making) | — (loss-making) | −100.78% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $3.2M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $3.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | |
| APVO Aptevo Therapeutics Inc. | $3.1M | 0.0× | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.1M | 0.0× | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $3.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $3.2M | — | — | −100.00% | — | +4.22% | 0.00% | 0.00% |
60 Degrees Pharmaceuticals Inc. (SXTP) key facts
- Strength: 60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024.
- 60 Degrees Pharmaceuticals Inc. (SXTP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SXTP traded at $0.86, a market capitalization of $3.2 million.
- Return on equity was 124.8% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −15.91 (distress zone) for fiscal 2025.